FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592005098> ?p ?o ?g. }

• W2592005098 abstract "Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and activated by DNA strand breaks. DNA damage from carboplatin is associated with activation of PARP. Preclinical data indicate that PARP inhibition potentiates the anti-tumor effect of platinum chemotherapy. Talazoparib (T) is an oral, selective PARP inhibitor with a single agent maximum tolerated dose (MTD) of 1mg orally qd. Primary dose-limiting toxicity (DLT) was thrombocytopenia. This phase I study combines T with the commonly used chemotherapy regimen of carboplatin (C) and paclitaxel (P). Methods: Two dosing schedules are being investigated. In both schedules, C is administered on day 1 and P on days 1, 8, and 15 of a 21-day cycle. T (100-1000mcg) is dosed once daily for days 1-7 (schedule A) or days 1-3 (schedule B) starting on day 1. A 3+3 design is used for dose escalation. Key eligibility criteria include age 318 with a measurable or evaluable solid incurable malignancy. Patients (pts) must have tumor type that is expected to respond to C + P or have BRCA germline or somatic mutation. Stable, treated brain metastases are allowed. No prior C for metastatic disease is allowed. Pts must have platelets>150 and no need for anticoagulation. After 4-6 cycles of combination therapy, pts may continue the combination, change to C and intermittent T without P or change to T alone with continuous daily dosing. Each schedule will have a 6 subject dose expansion at the MTD. The starting dose level for schedule B will be the MTD from schedule A. Results: Schedule A cohort results are reported: 11 pts (median age 59 [range 39-68]; 8 female; 3 male) have been enrolled. Pts had breast (6), ovarian (2), pancreatic (1), and SCC of oropharynx (1) and concurrent ovarian and pancreatic (1). Five pts are BRCA2+ and 3 pts are BRCA1+. Dose level 3 on schedule A (T 350mcg with C AUC 6 and P 80mg/m2) exceeded the MTD with 2 of 3 pts experiencing hematologic dose limiting toxicities (DLTs) including 1 pt with grade (gr) 3 neutropenic fever and gr 4 thrombocytopenia and another pt with grade 3/4 neutropenia lasting > 7 days. Most common AEs include neutropenia (grade 3-4: 7), anemia (grade 3-4: 3), and thrombocytopenia (grade 3-4: 4). Results from expansion of dose level 2 (T 250mcg with C AUC 6 and T 80mg/m2) will be presented. The 11 pts were on study a median of 9 weeks (range 9-36+). Four pts have discontinued study therapy: 1 due to need for anticoagulation for PE, 1 for prolonged cytopenias, and 2 for disease progression. Of the 8 pts with measurable disease evaluated for response to date, 4 had SD, 1 had a cPR, 1 had radiographic CR, and 2 with PD. A pt with BRCA 1+ triple negative breast cancer has maintained a prolonged PR (36+ weeks) even after dose reductions to T 100mcg with C AUC 3. One pt with ovarian cancer (BRCA WT) has radiographic CR (CA 125 remains mildly elevated) after 15+ weeks of therapy. Conclusion: PARP inhibition with talazoparib days 1-7 in combination with carboplatin and paclitaxel leads to DLT of myelosuppression. However, clinical responses are seen even with lower dose combinations. Citation Format: Turk A, Chan N, Leal T, O9Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-21." @default.
• W2592005098 created "2017-03-16" @default.
• W2592005098 creator A5008762690 @default.
• W2592005098 creator A5011579642 @default.
• W2592005098 creator A5016348831 @default.
• W2592005098 creator A5024711569 @default.
• W2592005098 creator A5030878684 @default.
• W2592005098 creator A5037003848 @default.
• W2592005098 creator A5050917158 @default.
• W2592005098 creator A5053602981 @default.
• W2592005098 creator A5060962310 @default.
• W2592005098 creator A5061916566 @default.
• W2592005098 creator A5076344697 @default.
• W2592005098 creator A5081735541 @default.
• W2592005098 creator A5091511322 @default.
• W2592005098 date "2017-02-15" @default.
• W2592005098 modified "2023-10-14" @default.
• W2592005098 title "Abstract P4-22-21: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors" @default.
• W2592005098 doi "https://doi.org/10.1158/1538-7445.sabcs16-p4-22-21" @default.
• W2592005098 hasPublicationYear "2017" @default.
• W2592005098 type Work @default.
• W2592005098 sameAs 2592005098 @default.
• W2592005098 citedByCount "0" @default.
• W2592005098 crossrefType "proceedings-article" @default.
• W2592005098 hasAuthorship W2592005098A5008762690 @default.
• W2592005098 hasAuthorship W2592005098A5011579642 @default.
• W2592005098 hasAuthorship W2592005098A5016348831 @default.
• W2592005098 hasAuthorship W2592005098A5024711569 @default.
• W2592005098 hasAuthorship W2592005098A5030878684 @default.
• W2592005098 hasAuthorship W2592005098A5037003848 @default.
• W2592005098 hasAuthorship W2592005098A5050917158 @default.
• W2592005098 hasAuthorship W2592005098A5053602981 @default.
• W2592005098 hasAuthorship W2592005098A5060962310 @default.
• W2592005098 hasAuthorship W2592005098A5061916566 @default.
• W2592005098 hasAuthorship W2592005098A5076344697 @default.
• W2592005098 hasAuthorship W2592005098A5081735541 @default.
• W2592005098 hasAuthorship W2592005098A5091511322 @default.
• W2592005098 hasConcept C121608353 @default.
• W2592005098 hasConcept C126322002 @default.
• W2592005098 hasConcept C126894567 @default.
• W2592005098 hasConcept C143998085 @default.
• W2592005098 hasConcept C181199279 @default.
• W2592005098 hasConcept C182979987 @default.
• W2592005098 hasConcept C185592680 @default.
• W2592005098 hasConcept C2776694085 @default.
• W2592005098 hasConcept C2777288759 @default.
• W2592005098 hasConcept C2777292972 @default.
• W2592005098 hasConcept C2778239845 @default.
• W2592005098 hasConcept C2779138821 @default.
• W2592005098 hasConcept C2779962180 @default.
• W2592005098 hasConcept C2781413609 @default.
• W2592005098 hasConcept C2781451048 @default.
• W2592005098 hasConcept C55493867 @default.
• W2592005098 hasConcept C71924100 @default.
• W2592005098 hasConcept C82381507 @default.
• W2592005098 hasConcept C98274493 @default.
• W2592005098 hasConceptScore W2592005098C121608353 @default.
• W2592005098 hasConceptScore W2592005098C126322002 @default.
• W2592005098 hasConceptScore W2592005098C126894567 @default.
• W2592005098 hasConceptScore W2592005098C143998085 @default.
• W2592005098 hasConceptScore W2592005098C181199279 @default.
• W2592005098 hasConceptScore W2592005098C182979987 @default.
• W2592005098 hasConceptScore W2592005098C185592680 @default.
• W2592005098 hasConceptScore W2592005098C2776694085 @default.
• W2592005098 hasConceptScore W2592005098C2777288759 @default.
• W2592005098 hasConceptScore W2592005098C2777292972 @default.
• W2592005098 hasConceptScore W2592005098C2778239845 @default.
• W2592005098 hasConceptScore W2592005098C2779138821 @default.
• W2592005098 hasConceptScore W2592005098C2779962180 @default.
• W2592005098 hasConceptScore W2592005098C2781413609 @default.
• W2592005098 hasConceptScore W2592005098C2781451048 @default.
• W2592005098 hasConceptScore W2592005098C55493867 @default.
• W2592005098 hasConceptScore W2592005098C71924100 @default.
• W2592005098 hasConceptScore W2592005098C82381507 @default.
• W2592005098 hasConceptScore W2592005098C98274493 @default.
• W2592005098 hasLocation W25920050981 @default.
• W2592005098 hasOpenAccess W2592005098 @default.
• W2592005098 hasPrimaryLocation W25920050981 @default.
• W2592005098 hasRelatedWork W11047152 @default.
• W2592005098 hasRelatedWork W11219607 @default.
• W2592005098 hasRelatedWork W1571712 @default.
• W2592005098 hasRelatedWork W16800841 @default.
• W2592005098 hasRelatedWork W17308044 @default.
• W2592005098 hasRelatedWork W370487 @default.
• W2592005098 hasRelatedWork W6339096 @default.
• W2592005098 hasRelatedWork W7849647 @default.
• W2592005098 hasRelatedWork W9134849 @default.
• W2592005098 hasRelatedWork W9793405 @default.
• W2592005098 isParatext "false" @default.
• W2592005098 isRetracted "false" @default.
• W2592005098 magId "2592005098" @default.
• W2592005098 workType "article" @default.